{"id":"W4380323763","doi":"10.1186/s13058-023-01649-w","title":"XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease","year":2023,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada); Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Exemestane; Medicine; Everolimus; Internal medicine; Breast cancer; Hazard ratio; Tolerability; Placebo; Oncology; Metastatic breast cancer; Clinical endpoint; Aromatase inhibitor; Cancer; Clinical trial; Adverse effect; Confidence interval; Aromatase; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001811557,0.0004730487,0.001058903,0.001294274,0.0002534686,0.0001015591,0.0002027242,0.0001302608,0.0001347038],"category_scores_gemma":[0.0001375558,0.0003745259,0.00005512126,0.002555151,0.001062638,0.0004385566,0.0002855758,0.0009186972,0.000002521122],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001184274,"about_ca_system_score_gemma":0.001975806,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01376052,"about_ca_topic_score_gemma":0.002632847,"domain_scores_codex":[0.9941999,0.0005733161,0.0006911113,0.001063496,0.002327307,0.00114489],"domain_scores_gemma":[0.9967991,0.0006074145,0.0002074477,0.0004490822,0.001137841,0.0007991783],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9312493,0.002373331,0.0349162,0.000583642,0.0003554421,0.0002297395,0.001727708,0.00004729106,0.0004345264,0.00001989484,0.0002206033,0.02784239],"study_design_scores_gemma":[0.6107399,0.00710141,0.3791557,0.001168975,0.0001354872,0.0000169103,0.0003884253,0.0008124697,0.0001475874,0.00002455131,0.00001865921,0.0002898638],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878469,0.0006580889,0.000004512684,0.002721531,0.00009030184,0.007582927,0.0009734645,0.00003227555,0.00009002762],"genre_scores_gemma":[0.9936924,0.00299975,0.00006501332,0.00002880407,0.0001061104,0.002567765,0.0001880293,0.0001049369,0.0002471653],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3442395,"threshold_uncertainty_score":0.9998707,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05492335571633707,"score_gpt":0.3966304399903068,"score_spread":0.3417070842739697,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}